Navigation Links
Anesiva to Unveil Zingo(TM) Commercialization Plans
Date:10/4/2007

SOUTH SAN FRANCISCO, Oct 4 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it will host a briefing for the investment community to review the company's launch and commercialization plans for Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system. The briefing will take place on Friday October 12, 2007 from noon to 1:30 p.m. Eastern Time in New York City. To access the live audio broadcast or the subsequent archived recording, please visit http://www.anesiva.com.

Anesiva's management and will review the company's manufacturing and commercialization plans as well as the timeline for the Zingo launch. The meeting will also feature William T. Zempsky, M.D., a pediatric pain specialist and associate professor of Pediatrics and Emergency Medicine at the University of Connecticut School of Medicine, who will discuss clinical experience with Zingo and the role it can play in pediatric medicine.

About Zingo

Zingo is a ready-to-use, single-use, needle-free system that delivers sterile lidocaine powder into the epidermis of the skin and provides topical, local analgesia in one to three minutes after administration. This rapid onset, which may be especially useful in pediatric populations and busy emergency room settings, means the product can be incorporated into a medical procedure allowing uninterrupted care, an important advantage over current options. In addition to the hospital setting, Zingo may be used in physicians' offices and clinical laboratories. Anesiva also recently completed enrollment of a Phase 3 trial evaluating Zingo in adults with the goal of expanding the label beyond the pediatric population.

About Anesiva and its Diverse Portfolio of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, to reduce pain associated with peripheral venous access procedures in children three to 18 years of age. The second product in Anesiva's pipeline, Adlea(TM) (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
2. Canine Painkiller unveiled by Novartis
3. Skin cancers secrets unveiled
4. Pfizer unveils anti-smoking drug
5. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
6. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
7. Study Unveils New Insight To The Madness Of King George III
8. Bush Unveils Latest Blueprint for Handling Bird Flu Pandemic
9. Rae unveils Health-care Strategy
10. Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development
11. New Health Insurance Scheme for Diabetics Unveiled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... LunchSkins is changing the ... replace billions of single-use, throw away plastic baggies. The mission-driven bags give back to ... life. , “The LunchSkins mission is all about reducing global plastic waste ...
(Date:5/3/2016)... (PRWEB) , ... May 03, ... ... Carnival Cruise Lines premiered the state-of-the-art Carnival Vista – the line’s largest ... ship, The Cruise Web has created an infographic spotlighting the Carnival ...
(Date:5/2/2016)... ... May 02, 2016 , ... It has just been ... keynote speaker for five events throughout the month of May. , Uldrich is the ... national news outlets. He also frequently appears on the Science Channel’s FutureScape and Discovery ...
(Date:5/2/2016)... Dallas, Texas (PRWEB) , ... May 02, 2016 ... ... Volume 3, Issue 1 of Patient Experience Journal (PXJ), an international, open ... patient experience. With almost half the issue representing international (non-US) based authors, the ...
(Date:5/2/2016)... ... May 02, 2016 , ... Beanfields, PBC, ... by partnering with college students at University of Colorado in Boulder to create ... advertising campaigns class in the School of Journalism, who selected Beanfields as the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... TOKYO , April 28, 2016 ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for ... and Pharmacovigilance team to bring a wealth of insight to a ... unparalleled pharmacovigilance knowledge. George Phillips joined ArisGlobal ...
(Date:4/28/2016)... -- TapImmune,Inc. (TPIV), a clinical-stage immune-oncology ... immunotherapeutics and vaccines for the treatment of cancer & metastatic ... Annual Growth Capital Expo to be held on May ... Palace in Las Vegas, Nevada.  The Company presentation will ... by Dr. John N. Bonfiglio a TapImmune ...
Breaking Medicine Technology: